Audio is streamed directly from the publisher (media.blubrry.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on October 23, 2025
Michael J. Mauro, MD
Director, Chronic Myeloid Leukemia Program
Professor of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!
Director, Chronic Myeloid Leukemia Program
Professor of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY